Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 24

Results For "research-and-development"

405 News Found

Kiran Mazumdar-Shaw awarded H. K. Firodia Lifetime Achievement Award 2022
People | September 26, 2022

Kiran Mazumdar-Shaw awarded H. K. Firodia Lifetime Achievement Award 2022

The committee unanimously decided to confer the Lifetime Achievement Award to Kiran Mazumdar-Shaw for her monumental contributions as a global leader in biotechnology innovation and entrepreneurship


Aptar Pharma collaborates with Fluidda
News | September 25, 2022

Aptar Pharma collaborates with Fluidda

The companies will leverage their respective proprietary technology platforms


Lupin receives approval from US FDA for Diclofenac Sodium Topical Solution USP
Drug Approval | September 23, 2022

Lupin receives approval from US FDA for Diclofenac Sodium Topical Solution USP

Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US


Aster Hospitals Bangalore launches 'Aster International Institute of Oncology'
Healthcare | September 22, 2022

Aster Hospitals Bangalore launches 'Aster International Institute of Oncology'

This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.


SIRIO appoints Lonza’s Sara Lesina as General Manager in Europe
People | September 08, 2022

SIRIO appoints Lonza’s Sara Lesina as General Manager in Europe

Her appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources


Ashland to expand bioresorbable polymers capacity in Ireland
News | September 02, 2022

Ashland to expand bioresorbable polymers capacity in Ireland

The capital expansion program commenced in June 2022 and is expected to complete in 2024


Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian
Diagnostic Center | September 01, 2022

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke


Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA
Diagnostic Center | September 01, 2022

Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA

COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan


Cipla (EU) to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical
News | August 31, 2022

Cipla (EU) to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical

Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.


SciGenom announces Phd program in collaboration with CHARUSAT University
News | August 29, 2022

SciGenom announces Phd program in collaboration with CHARUSAT University

This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists